60 Degrees Pharmaceuticals (SXTP) Share-based Compensation (2023 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Share-based Compensation of $79524.0 for Q1 2026, down 44.25% year-over-year from $142645.0 in Q1 2025, and up 163.8% quarter-over-quarter from -$124645.0 in Q2 2025.
60 Degrees Pharmaceuticals (SXTP) Share-based Compensation (2023 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Share-based Compensation for 4 consecutive years, with $79524.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 44.25% year-over-year to $79524.0; the TTM figure through Mar 2026 stood at -$45121.0 (down 101.56% YoY), while the FY2025 annual figure was $18000.0, changed N/A from the prior year.
- Share-based Compensation rose to $79524.0 in Q1 2026 per SXTP's latest filing, from -$124645.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.4 million in Q1 2023 and bottomed at -$5.1 million in Q2 2023.
- Historically, Share-based Compensation has averaged $338505.6 across 4 years, with a median of $79524.0 in 2026.
- Annual changes were most pronounced in 2024 — Share-based Compensation plunged 104.82% — and 2025, when it jumped 1602.61%.
- 60 Degrees Pharmaceuticals' Share-based Compensation stood at $316321.0 in 2023, then slumped by 104.82% to -$15246.0 in 2024, then tumbled by 717.56% to -$124645.0 in 2025, then jumped by 163.8% to $79524.0 in 2026.
- Business Quant data shows SXTP's Share-based Compensation at $79524.0 in Q1 2026, -$124645.0 in Q2 2025, and $142645.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | 46,978.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79,524.00 |
| Mar 31, 2026 | 79,524.00 |
| Jun 30, 2025 | -124,645.00 |
| Jun 30, 2025 | -124,645.00 |
| Mar 31, 2025 | 142,645.00 |
| Mar 31, 2025 | 142,645.00 |
| Dec 31, 2024 | -15,246.00 |
| Dec 31, 2024 | -15,246.00 |
| Sep 30, 2024 | 15,246.00 |
| Sep 30, 2024 | 15,246.00 |
| Jun 30, 2024 | 2.75 Mn |
| Jun 30, 2024 | 2.75 Mn |
| Mar 31, 2024 | 8,378.00 |
| Mar 31, 2024 | 8,378.00 |
| Dec 31, 2023 | 316,321.00 |
| Dec 31, 2023 | 316,321.00 |
| Sep 30, 2023 | 271,066.00 |
| Sep 30, 2023 | 271,066.00 |
| Jun 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -5.10 Mn |